RAPP Rapport Therapeutics, Inc.
$25.33▼ -2.31%
Healthcare
Other
Pre-market
$25.72▲ +1.55%
Oct 27, 7:04 AM ET
Volume 1.04M
Avg Volume (10D) 1.57M
Key Metrics & Fundamentals
Market Cap
$1.22B
P/E Ratio
–
Div Yield
0.00%
52W Range
23.75 - 52.93
% vs 50 MA
-34.39%
% vs 200 MA
-29.06%
RSI-14
29.4
MACD Histogram
+0.0300
Beta (1Y vs SPY)
1.19
Free Cash Flow
-$41.53M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$60.59M
COGS
–
Operating Exp
$60.81M
Operating Income
-$60.81M
EBIT
-$60.81M
Pretax Income
-$56.62M
Net Income
-$56.62M
EPS (Diluted)
-1.19
Price & Volume History
Loading chart…
Recent News
Rapport Therapeutics’ RAP-219 Hits Phase II Goals in Bipolar Mania Trial
MarketBeat · Oct 25, 2026 1:02 PM ET
Rapport Therapeutics (RAPP) Could Be 62% Below Fair Value Following Phase 2 Mania Data
Simply Wall St. · Oct 23, 2026 4:11 AM ET
Rapport Therapeutics (RAPP) Stock Gets Fair Value Boost After RAP 219 Bipolar Mania Data
Simply Wall St. · Oct 22, 2026 8:16 PM ET
Why Rapport Therapeutics (RAPP) Is Up 5.8% And What's Next
Simply Wall St. · Oct 22, 2026 6:20 PM ET
Rapport Therapeutics Insider Bought Shares Worth $974,278, According to a Recent SEC Filing
MT Newswires · Oct 22, 2026 5:03 PM ET
Can This Small Biotech Enter A $4.3 Billion AbbVie Market? Rapport Rises
Investor's Business Daily · Oct 20, 2026 4:28 PM ET
RAPP Stock Tempers Premarket Gains On Concerns Over Higher Discontinuation Rates In Bipolar Mania Study
Stocktwits · Oct 20, 2026 3:55 PM ET
Inside the $1 Billion Blockbuster Opportunity Sending Rapport Therapeutics Stock Higher
Barrons.com · Oct 20, 2026 3:46 PM ET
Raymond James Adjusts Rapport Therapeutics Price Target to $86 From $75, Maintains Strong Buy Rating
MT Newswires · Oct 20, 2026 12:55 PM ET
Rapport’s novel oral drug posts Phase II bipolar win
Clinical Trials Arena · Oct 20, 2026 12:31 PM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See RAPP's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.